Last reviewed · How we verify
Placebo of Levosimendan — Competitive Intelligence Brief
phase 3
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo of Levosimendan (Placebo of Levosimendan) — Assistance Publique - Hôpitaux de Paris. This is a placebo control arm and contains no active drug; it serves as a comparator in clinical trials of levosimendan.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo of Levosimendan TARGET | Placebo of Levosimendan | Assistance Publique - Hôpitaux de Paris | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo of Levosimendan CI watch — RSS
- Placebo of Levosimendan CI watch — Atom
- Placebo of Levosimendan CI watch — JSON
- Placebo of Levosimendan alone — RSS
Cite this brief
Drug Landscape (2026). Placebo of Levosimendan — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-of-levosimendan. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab